{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-18T12:15:55.319083+00:00","published_at":"2026-10-18T07:13:33.900852+00:00","section":"events","data":{"state":"PUBLISHED","derivation_version":"alpha-governance-event-derivation-v2","events":[{"event_id":"alpha:event:transition:1cr059b190wjp1","event_type":"CEO_CHANGED","effective_at":"2025-09-29","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:person:spyridon-spyros-papapetropoulos","alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:10"],"evidence_ids":["alpha:projection-evidence:document:409d3f30709b506cc42ba0ed090ce6ae1155611cff4c6d6b47304b60ad58496a"],"summary":"Spyros Papapetropoulos executive of Neuphoria Therapeutics Inc., effective 2025-09-29.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1jt2ixxaksmz5","event_type":"CFO_CHANGED","effective_at":"2025-09-29","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:person:tim-cunningham","alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:74ead60348041b00b6efe6e68d5e31566f0bc11c24272cfaece8eded56371478"],"summary":"Tim Cunningham executive of Neuphoria Therapeutics Inc., effective 2025-09-29.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1l8oypwsx5h4u","event_type":"DIRECTOR_APPOINTED","effective_at":"2023-01-01","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:person:spyridon-spyros-papapetropoulos","alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:9"],"evidence_ids":["alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7"],"summary":"Spyros Papapetropoulos seat on Neuphoria Therapeutics Inc., effective 2023-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1b9s9lz1dswya5","event_type":"DIRECTOR_APPOINTED","effective_at":"2021-01-01","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:person:peter-miles-davies","alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7"],"summary":"Peter Miles Davies seat on Neuphoria Therapeutics Inc., effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:qb1djtn1irl7","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:person:jane-ryan","alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7"],"summary":"Jane Ryan seat on Neuphoria Therapeutics Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:c73sipmdvy37","event_type":"COMMITTEE_CREATED","effective_at":"2020-01-01","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:committee:neuphoria-therapeutics-inc:audit-compensation-chair","alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7"],"summary":"Audit; Compensation · Chair committee of Neuphoria Therapeutics Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:pg06tg1r6r4ea","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2020-01-01","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:person:jane-ryan","alpha:committee:neuphoria-therapeutics-inc:audit-compensation-chair"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7"],"summary":"Jane Ryan member of Audit; Compensation · Chair, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1ep85ww69x6r4","event_type":"DIRECTOR_APPOINTED","effective_at":"2016-01-01","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:person:alan-fisher","alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7"],"summary":"Alan Fisher seat on Neuphoria Therapeutics Inc., effective 2016-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:kepmczxnho3n","event_type":"DIRECTOR_APPOINTED","effective_at":"2016-01-01","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:person:david-wilson","alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7"],"summary":"David Wilson seat on Neuphoria Therapeutics Inc., effective 2016-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:fdq6r4wna1mw","event_type":"COMMITTEE_CREATED","effective_at":"2016-01-01","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:committee:neuphoria-therapeutics-inc:audit-chair-compensation","alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7"],"summary":"Audit · Chair; Compensation committee of Neuphoria Therapeutics Inc., effective 2016-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:f710irs374x1","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2016-01-01","detected_at":"2026-10-18T07:13:33.900852+00:00","subject_ids":["alpha:person:alan-fisher","alpha:committee:neuphoria-therapeutics-inc:audit-chair-compensation"],"caused_claim_ids":["alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7"],"summary":"Alan Fisher member of Audit · Chair; Compensation, effective 2016-01-01.","derivation":"temporal_relationship_change"}]},"claims":[{"id":"alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:5","subject_id":"alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:alan-fisher","object_label":"Alan Fisher","object_source_name_forms":[],"value":"Alan Fisher: Director, Audit · Chair; Compensation","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:alan-fisher","name":"Alan Fisher"},"title":"Director","role_category":"director","committee":"Audit · Chair; Compensation","is_board_chair":false,"is_independent":true,"start_date":"2016-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2016-01-01","valid_to":null,"recorded_at":"2026-10-18T07:13:33.900852+00:00","sources":[{"id":"alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Neuphoria Therapeutics Inc. DEF 14A 2025-10-30","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000114036125039748/ny20055722x1_def14a.htm","source_date":"2025-10-30","retrieved_at":"2026-04-28T22:25:02.999+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-10-30","effective_from":"2016-01-01","effective_until":null,"observed_at":"2026-10-18T07:13:33.900852+00:00","reviewed_at":"2026-10-18T07:13:33.900852+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:6","subject_id":"alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:david-wilson","object_label":"David Wilson","object_source_name_forms":[],"value":"David Wilson: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:david-wilson","name":"David Wilson"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2016-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2016-01-01","valid_to":null,"recorded_at":"2026-10-18T07:13:33.900852+00:00","sources":[{"id":"alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Neuphoria Therapeutics Inc. DEF 14A 2025-10-30","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000114036125039748/ny20055722x1_def14a.htm","source_date":"2025-10-30","retrieved_at":"2026-04-28T22:25:02.999+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-10-30","effective_from":"2016-01-01","effective_until":null,"observed_at":"2026-10-18T07:13:33.900852+00:00","reviewed_at":"2026-10-18T07:13:33.900852+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:7","subject_id":"alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:jane-ryan","object_label":"Jane Ryan","object_source_name_forms":[],"value":"Jane Ryan: Director, Audit; Compensation · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:jane-ryan","name":"Jane Ryan"},"title":"Director","role_category":"director","committee":"Audit; Compensation · Chair","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-18T07:13:33.900852+00:00","sources":[{"id":"alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Neuphoria Therapeutics Inc. DEF 14A 2025-10-30","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000114036125039748/ny20055722x1_def14a.htm","source_date":"2025-10-30","retrieved_at":"2026-04-28T22:25:02.999+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-10-30","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-18T07:13:33.900852+00:00","reviewed_at":"2026-10-18T07:13:33.900852+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:8","subject_id":"alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:peter-miles-davies","object_label":"Peter Miles Davies","object_source_name_forms":[],"value":"Peter Miles Davies: Director, Audit","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:peter-miles-davies","name":"Peter Miles Davies"},"title":"Director","role_category":"director","committee":"Audit","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-18T07:13:33.900852+00:00","sources":[{"id":"alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Neuphoria Therapeutics Inc. DEF 14A 2025-10-30","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000114036125039748/ny20055722x1_def14a.htm","source_date":"2025-10-30","retrieved_at":"2026-04-28T22:25:02.999+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-10-30","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-18T07:13:33.900852+00:00","reviewed_at":"2026-10-18T07:13:33.900852+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:9","subject_id":"alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:spyridon-spyros-papapetropoulos","object_label":"Spyros Papapetropoulos","object_source_name_forms":[],"value":"Spyros Papapetropoulos: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:spyridon-spyros-papapetropoulos","name":"Spyros Papapetropoulos"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2023-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2023-01-01","valid_to":null,"recorded_at":"2026-10-18T07:13:33.900852+00:00","sources":[{"id":"alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Neuphoria Therapeutics Inc. DEF 14A 2025-10-30","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000114036125039748/ny20055722x1_def14a.htm","source_date":"2025-10-30","retrieved_at":"2026-04-28T22:25:02.999+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-10-30","effective_from":"2023-01-01","effective_until":null,"observed_at":"2026-10-18T07:13:33.900852+00:00","reviewed_at":"2026-10-18T07:13:33.900852+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:10","subject_id":"alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:spyridon-spyros-papapetropoulos","object_label":"Spyros Papapetropoulos","object_source_name_forms":[],"value":"Spyros Papapetropoulos: President, Chief Executive Officer, and Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:spyridon-spyros-papapetropoulos","name":"Spyros Papapetropoulos"},"title":"President, Chief Executive Officer, and Director","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2025-09-29","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2025-09-29","valid_to":null,"recorded_at":"2026-10-18T07:13:33.900852+00:00","sources":[{"id":"alpha:projection-evidence:document:409d3f30709b506cc42ba0ed090ce6ae1155611cff4c6d6b47304b60ad58496a","identity_scope":"source_document_reference","source_type":"sec_filing","title":"NEUP 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000119312525223338/neup-20250630.htm","source_date":"2025-09-29T00:00:00+00:00","retrieved_at":"2026-05-16T05:52:39.217407+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-09-29T00:00:00+00:00","effective_from":"2025-09-29","effective_until":null,"observed_at":"2026-10-18T07:13:33.900852+00:00","reviewed_at":"2026-10-18T07:13:33.900852+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6:leadership_role:11","subject_id":"alpha:company:aa1e8e3b-a123-4b0c-bf09-3ab420e4f5b6","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:tim-cunningham","object_label":"Tim Cunningham","object_source_name_forms":[],"value":"Tim Cunningham: Chief Financial Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:tim-cunningham","name":"Tim Cunningham"},"title":"Chief Financial Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2025-09-29","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2025-09-29","valid_to":null,"recorded_at":"2026-10-18T07:13:33.900852+00:00","sources":[{"id":"alpha:projection-evidence:document:74ead60348041b00b6efe6e68d5e31566f0bc11c24272cfaece8eded56371478","identity_scope":"source_document_reference","source_type":"sec_filing","title":"NEUP 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000119312525223338/neup-20250630.htm","source_date":"2025-09-29T00:00:00+00:00","retrieved_at":"2026-05-16T05:52:39.716893+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-09-29T00:00:00+00:00","effective_from":"2025-09-29","effective_until":null,"observed_at":"2026-10-18T07:13:33.900852+00:00","reviewed_at":"2026-10-18T07:13:33.900852+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:dd41a47c4122dfe25b3aff5699e7b3de83c7c6fd68839039ea20838a91caa0f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Neuphoria Therapeutics Inc. DEF 14A 2025-10-30","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000114036125039748/ny20055722x1_def14a.htm","source_date":"2025-10-30","retrieved_at":"2026-04-28T22:25:02.999+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:409d3f30709b506cc42ba0ed090ce6ae1155611cff4c6d6b47304b60ad58496a","identity_scope":"source_document_reference","source_type":"sec_filing","title":"NEUP 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000119312525223338/neup-20250630.htm","source_date":"2025-09-29T00:00:00+00:00","retrieved_at":"2026-05-16T05:52:39.217407+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:74ead60348041b00b6efe6e68d5e31566f0bc11c24272cfaece8eded56371478","identity_scope":"source_document_reference","source_type":"sec_filing","title":"NEUP 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000119312525223338/neup-20250630.htm","source_date":"2025-09-29T00:00:00+00:00","retrieved_at":"2026-05-16T05:52:39.716893+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.833,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.856,"cross_source_agreement":0.75,"temporal_completeness":0.583},"diagnostics":{"published_claims":18,"factual_claims":18,"claims_with_linked_evidence":18,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":12,"temporal_claims_with_valid_from":7,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-18T07:13:33.900852+00:00","observed_at":"2026-10-18T07:13:33.900852+00:00","reviewed_at":"2026-10-18T07:13:33.900852+00:00","verified_at":"2026-10-18T07:13:33.900852+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":18,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/neuphoria-therapeutics-inc/events","section":"events","href":"https://registry.alpha.ac/api/public/companies/neuphoria-therapeutics-inc?format=record&section=events","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}